Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

The presence of epoxyeicosatrienoic acids (EETs) in tissues and their metabolism by soluble epoxide hydrolase (sEH) to 1,2-diols were first reported 30 years ago. However, appreciation of their importance in cell biology and physiology has greatly accelerated over the past decade with the discovery of metabolically stable inhibitors of sEH, the commercial availability of EETs, and the development of analytical methods for the quantification of EETs and their diols. Numerous roles of EETs in regulatory biology now are clear, and the value of sEH inhibition in various animal models of disease has been demonstrated. Here, we review these results and discuss how the pharmacological stabilization of EETs and other natural epoxy-fatty acids could lead to possible disease therapies.

[1]  Yuan Zhang,et al.  Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction. , 2013, International journal of cardiology.

[2]  R. Abraham,et al.  The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. , 2013, Annual review of pharmacology and toxicology.

[3]  Jun Yang,et al.  Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. , 2012, American journal of respiratory cell and molecular biology.

[4]  H. Krum,et al.  Evaluation of the effects of urotensin II and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients. , 2012, Cardiovascular therapeutics.

[5]  B. Hammock,et al.  Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. , 2012, Biochemical and biophysical research communications.

[6]  W. Kong,et al.  Homocysteine Upregulates Soluble Epoxide Hydrolase in Vascular Endothelium In Vitro and In Vivo , 2012, Circulation research.

[7]  C. Thuillez,et al.  Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension , 2012, Circulation.

[8]  B. Hammock,et al.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. , 2012, Journal of medicinal chemistry.

[9]  Shuiping Zhao,et al.  Soluble epoxide hydrolase and ischemic cardiomyopathy. , 2012, International journal of cardiology.

[10]  M. Cazzola,et al.  Emerging drugs for chronic obstructive pulmonary disease , 2012, Expert opinion on emerging drugs.

[11]  Sampathkumar Anandan,et al.  Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects , 2012, Journal of clinical pharmacology.

[12]  G. Belcaro,et al.  Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. , 2012, Panminerva medica.

[13]  P. Poirier,et al.  The cardiovascular effects of peroxisome proliferator-activated receptor agonists. , 2012, The American journal of medicine.

[14]  C. Chen,et al.  Delivery of AAV2-CYP2J2 protects remnant kidney in the 5/6-nephrectomized rat via inhibition of apoptosis and fibrosis. , 2012, Human gene therapy.

[15]  Donald E Ingber,et al.  Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. , 2012, The Journal of clinical investigation.

[16]  S. Hwang,et al.  Pharmacological Inhibition of Soluble Epoxide Hydrolase Ameliorates Diet-Induced Metabolic Syndrome in Rats , 2011, Experimental diabetes research.

[17]  John D Imig,et al.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology. , 2012, Physiological reviews.

[18]  T. Corte,et al.  Pulmonary hypertension in 2012: contemporary issues in diagnosis and management. , 2012, Panminerva medica.

[19]  B. Hammock,et al.  Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception. , 2011, Prostaglandins & other lipid mediators.

[20]  S. Hwang,et al.  Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy , 2011, Cancer biology & therapy.

[21]  A. Pozzi,et al.  EET signaling in cancer , 2011, Cancer and Metastasis Reviews.

[22]  I. Fleming.  The cytochrome P450 pathway in angiogenesis and endothelial cell biology , 2011, Cancer and Metastasis Reviews.

[23]  S. Hwang,et al.  Inhibition of soluble epoxide hydrolase improves the impaired pressure–natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats , 2011, Journal of hypertension.

[24]  Xin A. Zhang,et al.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. , 2011, Advanced drug delivery reviews.

[25]  V. Richard,et al.  Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? , 2011, Pharmacology & therapeutics.

[26]  W. Pang,et al.  Activation of peroxisome proliferator‐activated receptor‐γ downregulates soluble epoxide hydrolase in cardiomyocytes , 2011, Clinical and experimental pharmacology & physiology.

[27]  J. Falck,et al.  Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats. , 2011, American journal of physiology. Heart and circulatory physiology.

[28]  F. Haj,et al.  Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance , 2011, Proceedings of the National Academy of Sciences.

[29]  S. Hwang,et al.  Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. , 2011, Journal of medicinal chemistry.

[30]  B. Hammock,et al.  Soluble epoxide hydrolase inhibitors and heart failure. , 2011, Cardiovascular therapeutics.

[31]  S. Hwang,et al.  Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[32]  B. Hammock,et al.  Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP , 2011, Proceedings of the National Academy of Sciences.

[33]  D. Harder,et al.  Cytochrome P450 eicosanoids and cerebral vascular function , 2011, Expert Reviews in Molecular Medicine.

[34]  Pei H. Cui,et al.  The ω‐3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down‐regulation , 2011, British journal of pharmacology.

[35]  C. Serhan,et al.  Novel anti-inflammatory--pro-resolving mediators and their receptors. , 2011, Current topics in medicinal chemistry.

[36]  E. Jacobs,et al.  Stable EET urea agonist and soluble epoxide hydrolase inhibitor regulate rat pulmonary arteries through TRPCs , 2011, Hypertension Research.

[37]  Li Xing,et al.  Discovery of potent inhibitors of soluble epoxide hydrolase by combinatorial library design and structure-based virtual screening. , 2011, Journal of medicinal chemistry.

[38]  K. Tomer,et al.  Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  I. Fleming,et al.  Cytochrome P450-Derived Epoxyeicosatrienoic Acids and Pulmonary Hypertension: Central Role of Transient Receptor Potential C6 Channels , 2011, Journal of cardiovascular pharmacology.

[40]  R. Ingraham,et al.  Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions. , 2011, Current medicinal chemistry.

[41]  M. Arand,et al.  Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase , 2011, Journal of Lipid Research.

[42]  D. Zeldin,et al.  Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) Is Associated With Forearm Vasodilator Responses in Humans , 2011, Hypertension.

[43]  R. Brandes,et al.  Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation , 2011, Molecular pain.

[44]  B. Hammock,et al.  Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids[S] , 2010, Journal of Lipid Research.

[45]  R. Albadine,et al.  17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. , 2010, American journal of respiratory cell and molecular biology.

[46]  R. Roman,et al.  20-Hydroxyeicosatetraeonic Acid: A New Target for the Treatment of Hypertension , 2010, Journal of cardiovascular pharmacology.

[47]  Jun Yang,et al.  Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events , 2010, Proceedings of the National Academy of Sciences.

[48]  B. Hammock,et al.  DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1-dependent mechanism. , 2010, Biochimica et biophysica acta.

[49]  S. Hwang,et al.  Inhibition of the Soluble Epoxide Hydrolase Promotes Albuminuria in Mice with Progressive Renal Disease , 2010, PloS one.

[50]  S. Hwang,et al.  Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis , 2010, Journal of Pharmacology and Experimental Therapeutics.

[51]  J. Liao,et al.  Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. , 2010, American journal of translational research.

[52]  M. Poirot,et al.  Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands , 2010, Proceedings of the National Academy of Sciences.

[53]  Paul D. Jones,et al.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[54]  G. Gross,et al.  Review Article: Epoxyeicosatrienoic Acids: Novel Mediators of Cardioprotection , 2010, Journal of cardiovascular pharmacology and therapeutics.

[55]  J. Haeggström,et al.  Advances in eicosanoid research, novel therapeutic implications. , 2010, Biochemical and biophysical research communications.

[56]  M. Revermann.  Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man. , 2010, Current opinion in pharmacology.

[57]  S. Shaw,et al.  Epoxyeicosatrienoic acid analogs and vascular function. , 2010, Current medicinal chemistry.

[58]  S. Hwang,et al.  Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. , 2010, Biochemical pharmacology.

[59]  I. Fleming,et al.  Epoxyeicosatrienoic acids and endothelium-dependent responses , 2010, Pflügers Archiv - European Journal of Physiology.

[60]  D. Vaughan,et al.  Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue , 2010, Obesity.

[61]  J. Falck,et al.  Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. , 2010, Clinical science.

[62]  Craig R. Lee,et al.  Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. , 2010, Journal of molecular and cellular cardiology.

[63]  N. Farrow,et al.  Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase. , 2010, Bioorganic & medicinal chemistry letters.

[64]  S. Hwang,et al.  Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. , 2009, Journal of molecular and cellular cardiology.

[65]  J. Falck,et al.  Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[66]  J. Falck,et al.  Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism , 2009, Neuroscience.

[67]  J. Berger,et al.  A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[68]  I. Muegge,et al.  Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. , 2009, Journal of medicinal chemistry.

[69]  J. Falck,et al.  14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. , 2009, Journal of medicinal chemistry.

[70]  S. Hwang,et al.  Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo , 2009, Molecular Cancer Therapeutics.

[71]  J. Berger,et al.  Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. , 2009, Journal of medicinal chemistry.

[72]  J. Berger,et al.  Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[73]  R. D. Rudic,et al.  Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. , 2009, The American journal of pathology.

[74]  M. Arand,et al.  Mammalian epoxide hydrolases in xenobiotic metabolism and signalling , 2009, Archives of Toxicology.

[75]  A. A. Spector,et al.  Arachidonic acid cytochrome P450 epoxygenase pathway Work from my laboratory cited in this review was supported by National Institutes of Health grants HL049264 and HL072845. Published, JLR Papers in Press, October 23, 2008. , 2009, Journal of Lipid Research.

[76]  D. Chen,et al.  Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation and dyslipidemia in apolipoprotein E deficient mice infused with angiotensin II , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[77]  J. Marino.  Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. , 2009, Current topics in medicinal chemistry.

[78]  L. Marnett.  The COXIB experience: a look in the rearview mirror. , 2009, Annual review of pharmacology and toxicology.

[79]  Paul D. Jones,et al.  Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy , 2009, Proceedings of the National Academy of Sciences.

[80]  H. Hercule,et al.  Interaction Between P450 Eicosanoids and Nitric Oxide in the Control of Arterial Tone in Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[81]  D. Behm,et al.  Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[82]  Pomila Singh,et al.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases , 2009, Drugs of the Future.

[83]  Paul D. Jones,et al.  Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways , 2008, Proceedings of the National Academy of Sciences.

[84]  O. Fiehn,et al.  Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse Model , 2008, Journal of cardiovascular pharmacology.

[85]  P. Pratt,et al.  Antinociception Produced by 14,15-Epoxyeicosatrienoic Acid Is Mediated by the Activation of β-Endorphin and Met-Enkephalin in the Rat Ventrolateral Periaqueductal Gray , 2008, Journal of Pharmacology and Experimental Therapeutics.

[86]  Erin S. Bolstad,et al.  Protein quaternary structure and expression levels contribute to peroxisomal-targeting-sequence-1-mediated peroxisomal import of human soluble epoxide hydrolase. , 2008, Journal of molecular biology.

[87]  Martin Vingron,et al.  Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease , 2008, Nature Genetics.

[88]  C. Wheelock,et al.  Development of metabolically stable inhibitors of Mammalian microsomal epoxide hydrolase. , 2008, Chemical research in toxicology.

[89]  D. Grant,et al.  Distribution and Expression of Soluble Epoxide Hydrolase in Human Brain , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[90]  É. Rousseau,et al.  EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. , 2008, American journal of respiratory cell and molecular biology.

[91]  R. Traystman,et al.  Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. , 2008, Resuscitation.

[92]  B. Hammock,et al.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. , 2008, Biochimica et biophysica acta.

[93]  B. Hammock,et al.  The soluble epoxide hydrolase as a pharmaceutical target for hypertension. , 2007, Journal of cardiovascular pharmacology.

[94]  D. Kroetz,et al.  Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor α , 2007, Drug Metabolism and Disposition.

[95]  J. Falck,et al.  Characterization of 14,15-Epoxyeicosatrienoyl-Sulfonamides as 14,15-Epoxyeicosatrienoic Acid Agonists: Use for Studies of Metabolism and Ligand Binding , 2007, Journal of Pharmacology and Experimental Therapeutics.

[96]  Yi Fu,et al.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo , 2007, Proceedings of the National Academy of Sciences.

[97]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[98]  B. Hammock,et al.  Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice* , 2007, Journal of Biological Chemistry.

[99]  D. Kroetz,et al.  Cytochrome P 450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor , 2007 .

[100]  B. Hammock,et al.  Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[101]  B. Hammock,et al.  Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. , 2006, Life sciences.

[102]  N. Frossard,et al.  Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? , 2006, Fundamental & clinical pharmacology.

[103]  B. Hammock,et al.  Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.

[104]  B. Hammock,et al.  Substituted Adamantyl-Urea Inhibitors of the Soluble Epoxide Hydrolase Dilate Mesenteric Resistance Vessels , 2006, Journal of Pharmacology and Experimental Therapeutics.

[105]  J. Liao,et al.  Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease. , 2006, Trends in cardiovascular medicine.

[106]  E. Jacobs,et al.  Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[107]  D. Grant,et al.  Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. , 2006, Biochemical and biophysical research communications.

[108]  J. Shyy,et al.  The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[109]  B. Hammock,et al.  Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. , 2005, Biochemistry.

[110]  B. Hammock,et al.  Soluble epoxide hydrolase is a therapeutic target for acute inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Kevin R. Smith,et al.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[112]  B. Hammock,et al.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.

[113]  B. Hammock,et al.  Epoxide hydrolases: their roles and interactions with lipid metabolism. , 2005, Progress in lipid research.

[114]  J. Imig.  20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[115]  J. Falck,et al.  14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. , 2004, Pharmacological research.

[116]  Bruce D Hammock,et al.  Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. , 2004, Biochemistry.

[117]  D. Kroetz,et al.  Vascular localization of soluble epoxide hydrolase in the human kidney. , 2004, American journal of physiology. Renal physiology.

[118]  B. Hammock,et al.  Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. , 2004, Journal of medicinal chemistry.

[119]  M. Toborek,et al.  Involvement of CYP 2C9 in Mediating the Proinflammatory Effects of Linoleic Acid in Vascular Endothelial Cells , 2003, Journal of the American College of Nutrition.

[120]  J. E. Maxwell,et al.  Polymorphisms in human soluble epoxide hydrolase. , 2003, Molecular pharmacology.

[121]  B. Hammock,et al.  The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[122]  M. Fornage,et al.  Polymorphism in Soluble Epoxide Hydrolase and Blood Pressure in Spontaneously Hypertensive Rats , 2002, Hypertension.

[123]  C. Wheelock,et al.  Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. , 2002, Biochemical pharmacology.

[124]  F. Gonzalez,et al.  Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation* , 2000, The Journal of Biological Chemistry.

[125]  B D Hammock,et al.  Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids , 2000, Circulation research.

[126]  J. Meijer,et al.  Identification and Functional Characterization of Human Soluble Epoxide Hydrolase Genetic Polymorphisms* , 2000, The Journal of Biological Chemistry.

[127]  K. Ley,et al.  Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.

[128]  B D Hammock,et al.  Potent urea and carbamate inhibitors of soluble epoxide hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[129]  T. Lu,et al.  Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes , 1999, The Journal of physiology.

[130]  B. Borhan,et al.  Improved radiolabeled substrates for soluble epoxide hydrolase. , 1995, Analytical biochemistry.

[131]  D. Zeldin,et al.  Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. , 1993, The Journal of biological chemistry.

[132]  J. Falck,et al.  Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. , 1983, Biochemical and biophysical research communications.

[133]  H. Samuels,et al.  NOVEL HYPOTHALAMIC ARACHIDONATE PRODUCTS STIMULATE SOMATOSTATIN RELEASE FROM THE MEDIAN EMINENCE1 , 1983 .

[134]  R. Estabrook,et al.  The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. , 1983, Archives of biochemistry and biophysics.

[135]  S. Ojeda,et al.  Novel hypothalamic arachidonate products stimulate somatostatin release from the median eminence. , 1983, Endocrinology.

[136]  R. Estabrook,et al.  Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[137]  F. Oesch,et al.  Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.